- 7/24 Live Call Center
Stem cells can develop into many cell types and act as the body’s repair system. They replace or restore damaged tissues, offering new possibilities for treating diseases.
Send us all your questions or requests, and our expert team will assist you.
Myelodysplastic Syndromes (MDS) are a varied group of disorders that affect the blood-forming stem cells in the bone marrow. To understand MDS, it helps to know how blood is made. In healthy people, the bone marrow acts like a factory inside the bones, where stem cells constantly divide and mature. These stem cells can both renew themselves, so the supply never runs out, and develop into the main types of blood cells: red blood cells (for carrying oxygen), white blood cells (for fighting infection), and platelets (for clotting).
In MDS, the main problem is that stem cells do not mature properly. These cells develop genetic mutations, creating a group of abnormal cells. Unlike acute leukemia, where immature cells multiply too quickly, MDS is marked by poor blood cell production. The bone marrow is often crowded with developing cells, but many are misshapen and do not work well. Most of these abnormal cells die in the marrow before entering the bloodstream. As a result, even though the marrow is busy, the blood lacks enough healthy cells, causing low blood counts.
The terminology itself offers insight into the pathology. “Myelo” refers to the bone marrow, and “dysplastic” refers to the abnormal shape or morphology of the cells. Historically, these conditions were often referred to as “pre-leukemia” or “smoldering leukemia.” While it is true that MDS carries a significant risk of transforming into Acute Myeloid Leukemia (AML), the term “pre-leukemia” is somewhat insufficient. It fails to capture the morbidity and clinical complexity of the syndrome itself, which can be life-threatening due to marrow failure even if it never progresses to frank leukemia.
Myelodysplastic Syndromes start with problems in the blood-forming stem cells. Recent research shows that the issue is not just in the stem cells themselves, but also in the environment around them, called the “niche.” This niche is a special area in the bone marrow that helps control how stem cells work. In MDS, this environment becomes unhealthy or damaged.
According to the clonal evolution theory, a stem cell develops a DNA change during a person’s life (not inherited). This change helps the abnormal cell survive better than normal cells, so it grows and takes over the bone marrow. These abnormal cells often have changes in genes that control basic cell functions, like DNA methylation, RNA splicing, and chromatin modification. When these processes are disrupted, blood cell production becomes disorganized and ineffective, as seen in MDS.
This connection to stem cell biology is why regenerative medicine is central to the conversation about MDS. Since the disease is a fundamental corruption of the stem cell pool, the only way to definitively correct the error is often to replace the entire system. This is achieved through allogeneic hematopoietic stem cell transplantation. This procedure replaces the patient’s defective marrow with healthy donor stem cells, effectively regenerating a new, functional blood-forming organ.
Myelodysplastic Syndromes mostly affect older adults. The chance of getting MDS increases with age, and most people are diagnosed between 70 and 75 years old. This pattern suggests that MDS partly results from genetic damage that builds up over time. As we age, our stem cells collect mutations. Usually, these are harmless, but in MDS, they affect important genes that control cell growth.
MDS can also happen in younger adults and children, but this is rare and usually linked to inherited genetic conditions. Some cases are called “Therapy-Related MDS” (t-MDS), which develop in people who have had chemotherapy or radiation for other cancers. These treatments can damage bone marrow stem cells, sometimes causing a more aggressive form of MDS years later.
Understanding the epidemiology is crucial for public health and clinical planning. As the global population ages, the prevalence of MDS is expected to rise. This necessitates a robust healthcare infrastructure capable of managing chronic blood disorders and providing advanced regenerative therapies to an older population that may have other comorbidities.
The way doctors classify MDS has changed a lot over the past century. In the early 1900s, doctors described “refractory anemias,” which did not improve with iron or vitamin treatment. In the 1970s and 80s, the French-American-British (FAB) group created the first detailed system, using the percentage of immature cells (blasts) in the bone marrow to define MDS types.
Today, doctors use the World Health Organization (WHO) classification system, which is more advanced. It looks at both how the cells appear under the microscope and the genetic changes in the disease. This approach helps doctors predict outcomes and choose targeted treatments. For example, finding a specific chromosome change like del(5q) points to a type of MDS that responds well to certain drugs.
In the context of Liv Hospital and advanced medical centers, MDS is viewed through the lens of cellular therapy. The condition is the ultimate candidate for regenerative intervention because it represents a specific organ failure—the bone marrow. Unlike heart or kidney failure, where organ transplantation is a surgical procedure, bone marrow “transplantation” is a cellular infusion.
The philosophy of treating MDS has shifted from “palliative care” (managing symptoms with transfusions) to “disease modification” (altering the natural history of the disease). Stem cell research is currently investigating ways not only to replace the marrow but also to rejuvenate the aging stem cell niche or to target specific genetic clones without wiping out the entire marrow. This represents the frontier of hematologic research, moving towards less toxic and more precise regenerative solutions.
Send us all your questions or requests, and our expert team will assist you.
The primary difference lies in the maturity of the cells and the speed of progression. In MDS, the bone marrow cells are dysplastic and die prematurely, leading to low blood counts. In acute leukemia, the marrow is overwhelmed by immature blast cells that do not die but proliferate rapidly. MDS can progress to leukemia if the blast count rises above 20 percent.
Yes, the World Health Organization and most medical bodies classify Myelodysplastic Syndromes as a form of blood cancer. This is because it is a clonal disease caused by acquired genetic mutations and has the potential to progress and shorten life expectancy, similar to other malignancies.
The vast majority of MDS cases are acquired, meaning the genetic mutations occur by chance during the patient’s lifetime and are not inherited. However, rare familial forms of MDS are caused by inherited genetic predisposition. If multiple family members have had MDS or leukemia, genetic counseling is recommended.
Ineffective hematopoiesis refers to the process in which the bone marrow produces blood cells, but they are defective. Instead of maturing and entering the bloodstream to perform their functions, these cells undergo apoptosis (programmed cell death) while still inside the marrow. This results in a crowded marrow but “empty” blood.
Our cells accumulate genetic mutations over time as they divide. Since hematopoietic stem cells divide continuously throughout a lifespan to produce blood, they are prone to “wear and tear” damage. Older individuals have had more time to accumulate these random genetic errors, increasing the likelihood that one will disrupt a critical gene and lead to MDS.
Your Comparison List (you must select at least 2 packages)
